Navigation Links
Accelitech to Open the First CyberKnife Cancer Center Within the City of Chicago
Date:2/22/2012

CHICAGO, Feb. 22, 2012  /PRNewswire/ -- Accelitech LLC, a leading developer of stereotactic radiosurgery and cancer treatment programs, is pleased to announce its newest CyberKnife cancer center, which will begin treating patients in Chicago in the summer of 2012. Developed through a partnership between Accelitech, physicians and Swedish Covenant Hospital, the new CyberKnife Cancer Institute of Chicago will provide state-of-the-art CyberKnife treatment to patients from Chicago and beyond. This will be the first CyberKnife center within the city limits and will feature the latest technology of its kind in the region.

Centrally located and conveniently accessible from both downtown and suburban locations, the new 10,000-square-foot facility, now under construction, will be located at 160 East Illinois, in the heart of Chicago. The center will open and the clinical team will begin evaluating patients for treatment beginning this spring.

"Our vision is to create the very best setting for patient care and provide the most advanced cancer treatment technology available in the market," says Adam Dickler, MD, the Medical Director for the new CyberKnife center. "More than 20 cancer care physicians have been trained to use the CyberKnife, providing new treatment options for their patients."

"With this and every project, our goal is to bring new technology to patients who need it most, so we're very excited to add our Chicago site to a rapidly growing network of Accelitech CyberKnife centers," says Kerwin Brandt, CEO of Accelitech. "With nine existing locations and many more under development, we believe we are the largest and fastest growing private developer of CyberKnife centers in the country."

About Accelitech LLC

Accelitech LLC is a leading developer of stereotactic radiosurgery and cancer treatment programs. Headquartered in Chicago, IL, Accelitech is a privately held company with extensive experience and resources in healthcare, law, finance, development, and clinical operations. Accelitech provides the funds, expertise and legal models to allow physicians and hospitals to bring new technology to market for the benefit of the patients they serve. Accelitech has sites and projects under development throughout the United States.

For additional information about Accelitech and its services, please visit accelitech.biz.

About CyberKnife Cancer Institute of Chicago by Swedish Covenant Hospital

CyberKnife is the first and only robotic radiosurgery system delivering customizable, non-surgical treatments for a broad range of tumors anywhere in the body. Only the CyberKnife system allows practitioners to non-invasively deliver high doses of radiation to tumors with extreme accuracy and intense precision, providing personalized and tailored treatments that help clinicians pursue the best clinical outcomes for patients' individual needs. The CyberKnife Cancer Institute of Chicago will open the summer of 2012 and is located at 160 East Illinois, off of Michigan Avenue in Chicago.  For more information about the center's opening, visit accelitech.biz.

Media Inquiries:
Stacey McClenathan
Stacey@beecommunications.com


'/>"/>
SOURCE Accelitech LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... WELLESLEY, Massachusetts , May 26, 2016 ... sequencing (NGS) has matured into an essential life science ... research and development applications. BCC Research reveals in its ... of a second growth phase, one powered by a ... applied fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research Corp. ... their new reference materials that help researchers obtain ... collection to analyses. The rapid growth of the ... researchers to have standard methods to improve the ... Biases inherently exist at every step of the ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
(Date:5/26/2016)... ... 26, 2016 , ... MadgeTech will be showcasing its line of data ... Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries around ... including NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech ...
(Date:5/26/2016)... Farmingdale, NY (PRWEB) , ... May 26, 2016 ... ... and Hereditary Retinal Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on ... free to the public. , Dr. Maisel, founder of Retina Group of ...
(Date:5/26/2016)... ... ... In an effort to provide hair restoration information to the widest possible audience, Dr. Parsa ... not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making ... , Dr. Mohebi says, “The positive response to the Snapchat videos we started last month ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of healthcare supply chain solutions, today announced the organization has earned its ISO ... international standards and is compliant with all rules and policies associated with ISO ...
Breaking Medicine News(10 mins):